Market Spotlight: Uterine Cancer
|出版日期||內容資訊||英文 45 Pages
|關注市場分析:子宮癌 Market Spotlight: Uterine Cancer|
|出版日期: 2019年12月04日||內容資訊: 英文 45 Pages||
This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by
2028. In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by
2028. Merck & Co's Keytruda and Eisai's Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes, respectively.
The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in the NDA/BLA stage.
Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
High-impact upcoming events for the drugs in the uterine cancer space comprise topline Phase II trial results for XBIO-101, and an estimated PDUFA date for dostarlimab.
The overall likelihood of approval of a Phase I solid tumors asset is 5.7%, and the average probability a drug advances from Phase III is 41.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been nine licensing and asset acquisition deals involving endometrial cancer drugs during 2015-20. The $1,119m exclusive licensing agreement signed in 2016 between Exelixis and Ipsen, pursuant to which Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside the US, Canada and Japan, was the largest deal.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.
The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while France, Germany, Spain, and the UK lead the major European markets.
Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
AstraZeneca leads the industry sponsors with the highest overall number of clinical trials for uterine neoplasms
9 Radiation therapy
10 Hormone therapy
10 Palliative care
23 MGA012 for Uterine Cancer (July 2, 2019)
23 Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)
24 TAK-117 for Uterine Cancer (March 20, 2019)
25 Dostarlimab for Uterine Cancer (March 19, 2019)
27 DKN-01 for Uterine Cancer (March 18, 2019)
28 Dostarlimab for Uterine Cancer (October 20, 2018)
32 Dostarlimab Submitted For (Relatively) Broad Endometrial Cancer Indication
32 FDA Issues Pair Of RTOR Approvals To Keytruda/Lenvima Combo, Erleada
32 Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
34 Deals Shaping The Medical Industry, August 2019
38 Sponsors by status
39 Sponsors by phase
41 Prescription Information